Currently, there are three CDK4/6 inhibitors approved to treat breast cancer at different stages — Ibrance (chemical name: palbociclib), Kisqali (chemical name: ribociclib), and Verzenio (chemical ...
Verzenio’s label expanded to include the full study population investigated in the Verzenio Phase 3 monarchE trial. Approval supported by four-year data from the monarchE trial; Verzenio added to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback